» Articles » PMID: 28416466

Risk of Atrioesophageal Fistula Formation with Contact Force-sensing Catheters

Overview
Journal Heart Rhythm
Publisher Elsevier
Date 2017 Apr 19
PMID 28416466
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Atrioesophageal fistula formation is a rare but life-threatening complication of atrial fibrillation ablation. Contact force (CF)-sensing catheters improve procedural effectiveness. However, the impact of the implementation of CF-sensing technology on the risk of atrioesophageal fistula formation has not been explored.

Objective: The purpose of this study was to determine the association between the use of CF-sensing catheters and atrioesophageal fistula development.

Methods: We searched the Manufacturer and User Facility Device Experience database for adverse event reports involving Food and Drug Administration-approved ablation catheters.

Results: Among 2689 device reports, we identified 78 atrioesophageal fistula cases, 65 of which involved CF-sensing catheters and 13 non-CF-sensing catheters. The percentage of total reports involving atrioeosphageal fistula was 5.4% for CF-sensing catheters (65 of 1202) and 0.9% for non-CF-sensing catheters (13 of 1487) (P < .0001). Procedural details (CF and power settings) were not consistently reported. Esophageal temperature increases were detected in only 2.5% of cases (2 of 78). The mean time to presentation was 16 ± 9 days. Overall mortality was at least 56%, with patients who underwent surgical repair more likely to survive than those treated with stenting or no intervention.

Conclusion: Atrioesophageal fistula formation accounted for a much higher proportion of reported adverse events with CF-sensing catheters compared with non-CF-sensing catheters. Improved understanding of the relationship between power/force delivery and esophageal damage is needed to minimize the risk of atrioesophageal fistula formation.

Citing Articles

Proactive esophageal cooling during radiofrequency cardiac ablation: data update including applications in very high-power short duration ablation.

Sharkoski T, Zagrodzky J, Warrier N, Doshi R, Omotoye S, Mercado Montoya M Expert Rev Med Devices. 2024; 22(1):63-73.

PMID: 39720904 PMC: 11750608. DOI: 10.1080/17434440.2024.2447809.


Surveillance of esophageal injury after atrial fibrillation catheter ablation.

Ferraz A, Pisani C, Rivarola E, Wu T, Darrieux F, Scanavacca R J Interv Card Electrophysiol. 2024; .

PMID: 39436462 DOI: 10.1007/s10840-024-01922-8.


A New Hope for the Treatment of Atrial Fibrillation: Application of Pulsed-Field Ablation Technology.

Wang Z, Liang M, Sun J, Zhang J, Han Y J Cardiovasc Dev Dis. 2024; 11(6).

PMID: 38921675 PMC: 11204042. DOI: 10.3390/jcdd11060175.


Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data.

Li X, Feng Y, Gong Y, Chen Y J Patient Saf. 2024; 20(5):e45-e58.

PMID: 38470959 PMC: 11636620. DOI: 10.1097/PTS.0000000000001220.


Atrial Fibrillation Ablation: Current Practice and Future Perspectives.

Rottner L, Metzner A J Clin Med. 2023; 12(24).

PMID: 38137626 PMC: 10743921. DOI: 10.3390/jcm12247556.